BR112014026706A2 - método de tratamento para dermatoses responsivas a esteroides - Google Patents
método de tratamento para dermatoses responsivas a esteroidesInfo
- Publication number
- BR112014026706A2 BR112014026706A2 BR112014026706A BR112014026706A BR112014026706A2 BR 112014026706 A2 BR112014026706 A2 BR 112014026706A2 BR 112014026706 A BR112014026706 A BR 112014026706A BR 112014026706 A BR112014026706 A BR 112014026706A BR 112014026706 A2 BR112014026706 A2 BR 112014026706A2
- Authority
- BR
- Brazil
- Prior art keywords
- chloro
- methyl
- responsive dermatoses
- treatment method
- steroid
- Prior art date
Links
- 208000017520 skin disease Diseases 0.000 title abstract 3
- 150000003431 steroids Chemical class 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- AFJRDFWMXUECEW-LBPRGKRZSA-N N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methyl-3-pyrazolyl)-2-thiophenecarboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)SC(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)=C1 AFJRDFWMXUECEW-LBPRGKRZSA-N 0.000 abstract 1
- AXTAPYRUEKNRBA-JTQLQIEISA-N n-[(2s)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)OC(C(=O)N[C@H](CN)CC=2C=C(F)C(F)=CC=2)=C1 AXTAPYRUEKNRBA-JTQLQIEISA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261637390P | 2012-04-24 | 2012-04-24 | |
| US201361782565P | 2013-03-14 | 2013-03-14 | |
| PCT/EP2013/058249 WO2013160222A1 (en) | 2012-04-24 | 2013-04-22 | Treatment method for steroid responsive dermatoses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014026706A2 true BR112014026706A2 (pt) | 2017-06-27 |
Family
ID=48143295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014026706A BR112014026706A2 (pt) | 2012-04-24 | 2013-04-22 | método de tratamento para dermatoses responsivas a esteroides |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20150087683A1 (https=) |
| EP (1) | EP2841053A1 (https=) |
| JP (1) | JP2015514792A (https=) |
| KR (1) | KR20150010943A (https=) |
| CN (1) | CN104302275A (https=) |
| AR (1) | AR090795A1 (https=) |
| AU (1) | AU2013254849B2 (https=) |
| BR (1) | BR112014026706A2 (https=) |
| CA (1) | CA2873751A1 (https=) |
| CL (1) | CL2014002861A1 (https=) |
| CO (1) | CO7111283A2 (https=) |
| CR (1) | CR20140491A (https=) |
| DO (1) | DOP2014000238A (https=) |
| EA (1) | EA201491914A1 (https=) |
| HK (1) | HK1201726A1 (https=) |
| IL (1) | IL235159A0 (https=) |
| MX (1) | MX2014012904A (https=) |
| NZ (1) | NZ628394A (https=) |
| PE (1) | PE20142356A1 (https=) |
| PH (1) | PH12014502400A1 (https=) |
| SG (1) | SG11201406409VA (https=) |
| TW (1) | TW201347758A (https=) |
| UA (1) | UA113875C2 (https=) |
| UY (1) | UY34762A (https=) |
| WO (1) | WO2013160222A1 (https=) |
| ZA (1) | ZA201407345B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111821299A (zh) * | 2019-04-16 | 2020-10-27 | 天津合美医药科技有限公司 | 噻吩衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006002734A1 (en) * | 2004-07-01 | 2006-01-12 | Unilever N.V. | Moisture barrier |
| ES2368930T3 (es) * | 2004-09-06 | 2011-11-23 | Bayer Pharma Aktiengesellschaft | Pirazolopirimidinas como inhibidores de proteína cinasa b (akt). |
| AU2006235314B2 (en) * | 2005-04-12 | 2011-01-20 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| CN102405047B (zh) * | 2009-01-30 | 2014-07-09 | 葛兰素史密斯克莱有限责任公司 | 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐 |
| JP2013507382A (ja) * | 2009-10-08 | 2013-03-04 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 組合せ |
| WO2011146710A1 (en) * | 2010-05-21 | 2011-11-24 | Glaxosmithkline Llc | Combination |
-
2013
- 2013-04-22 US US14/394,394 patent/US20150087683A1/en not_active Abandoned
- 2013-04-22 BR BR112014026706A patent/BR112014026706A2/pt not_active IP Right Cessation
- 2013-04-22 PE PE2014001697A patent/PE20142356A1/es not_active Application Discontinuation
- 2013-04-22 CN CN201380025996.5A patent/CN104302275A/zh active Pending
- 2013-04-22 JP JP2015507484A patent/JP2015514792A/ja active Pending
- 2013-04-22 AR ARP130101336A patent/AR090795A1/es unknown
- 2013-04-22 NZ NZ628394A patent/NZ628394A/en not_active IP Right Cessation
- 2013-04-22 WO PCT/EP2013/058249 patent/WO2013160222A1/en not_active Ceased
- 2013-04-22 KR KR20147029737A patent/KR20150010943A/ko not_active Withdrawn
- 2013-04-22 HK HK15102257.7A patent/HK1201726A1/xx unknown
- 2013-04-22 UA UAA201412609A patent/UA113875C2/uk unknown
- 2013-04-22 MX MX2014012904A patent/MX2014012904A/es unknown
- 2013-04-22 EP EP13717779.6A patent/EP2841053A1/en not_active Withdrawn
- 2013-04-22 AU AU2013254849A patent/AU2013254849B2/en not_active Ceased
- 2013-04-22 SG SG11201406409VA patent/SG11201406409VA/en unknown
- 2013-04-22 EA EA201491914A patent/EA201491914A1/ru unknown
- 2013-04-22 CA CA2873751A patent/CA2873751A1/en not_active Abandoned
- 2013-04-22 TW TW102114114A patent/TW201347758A/zh unknown
- 2013-04-23 UY UY0001034762A patent/UY34762A/es not_active Application Discontinuation
-
2014
- 2014-10-09 ZA ZA2014/07345A patent/ZA201407345B/en unknown
- 2014-10-19 IL IL235159A patent/IL235159A0/en unknown
- 2014-10-23 CO CO14235154A patent/CO7111283A2/es unknown
- 2014-10-23 DO DO2014000238A patent/DOP2014000238A/es unknown
- 2014-10-23 CL CL2014002861A patent/CL2014002861A1/es unknown
- 2014-10-24 CR CR20140491A patent/CR20140491A/es unknown
- 2014-10-24 PH PH12014502400A patent/PH12014502400A1/en unknown
-
2016
- 2016-02-02 US US15/013,227 patent/US20160143885A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR090795A1 (es) | 2014-12-10 |
| CL2014002861A1 (es) | 2015-01-16 |
| MX2014012904A (es) | 2014-11-21 |
| EA201491914A1 (ru) | 2015-01-30 |
| AU2013254849A1 (en) | 2014-11-06 |
| SG11201406409VA (en) | 2014-11-27 |
| US20160143885A1 (en) | 2016-05-26 |
| TW201347758A (zh) | 2013-12-01 |
| CN104302275A (zh) | 2015-01-21 |
| CR20140491A (es) | 2014-12-22 |
| ZA201407345B (en) | 2015-11-25 |
| UA113875C2 (uk) | 2017-03-27 |
| CO7111283A2 (es) | 2014-11-10 |
| AU2013254849B2 (en) | 2016-05-26 |
| US20150087683A1 (en) | 2015-03-26 |
| HK1201726A1 (en) | 2015-09-11 |
| PH12014502400A1 (en) | 2015-01-12 |
| KR20150010943A (ko) | 2015-01-29 |
| CA2873751A1 (en) | 2013-10-31 |
| PE20142356A1 (es) | 2015-01-30 |
| EP2841053A1 (en) | 2015-03-04 |
| DOP2014000238A (es) | 2014-12-15 |
| IL235159A0 (en) | 2014-12-31 |
| WO2013160222A1 (en) | 2013-10-31 |
| UY34762A (es) | 2013-11-29 |
| JP2015514792A (ja) | 2015-05-21 |
| NZ628394A (en) | 2016-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| WO2015054619A3 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
| BR112015022197A2 (pt) | tratamento de cataplexia | |
| BR112017003546A2 (pt) | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos | |
| BR112013030894A2 (pt) | moduladores do sistema imune | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| MX384403B (es) | Terapia de combinación para el tratamiento del cáncer. | |
| EA201500365A1 (ru) | Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| BR112015021371A2 (pt) | uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares | |
| AR097178A1 (es) | Diagnóstico y terapias anticáncer que comprenden células madre cancerosas | |
| IN2015DN00376A (https=) | ||
| IN2015DN00450A (https=) | ||
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| EP2666471A4 (en) | PHARMACEUTICAL COMPOSITION FOR MILK AND LIVER AND MANUFACTURING METHOD THEREFOR | |
| BR112018003232A2 (pt) | terapias de combinação para tratamento de câncer | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| EA201890859A1 (ru) | Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112014010729A2 (pt) | métodos para tratamento de ataques de gota | |
| BR112017007138A2 (pt) | composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto. | |
| BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
| BR112015022846A2 (pt) | uso de um composto para tratar ou prevenir um angioedema mediado pelo receptor b2 da bradicinina e formulação compreendendo o mesmo | |
| BR112017008805A2 (pt) | tratamento de córnea usando laminina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: NOVARTIS PHARMA AG (CH) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: NOVARTIS AG (CH) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2515 DE 19-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |